GlassScriptPhysician profile
Erin Stutes Bourque
NPI 1396408886
$1,175.13
in general payments reported to CMS, 2019-2025
20 companies · $558 in 2025
The $558 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.36 · 2023: $363 · 2024: $240 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $229.79 | 2023-2025 | Aristada, Lybalvi |
| Indivior INC. | $146.13 | 2025 | Sublocade |
| Pfizer INC. | $93.66 | 2023-2025 | |
| Axsome Therapeutics, INC. | $87.96 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $83.68 | 2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Exact Sciences Corporation | $82.97 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $75.62 | 2024 | Uzedy, Austedo Xr |
| Lilly USA, LLC | $59.99 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Dexcom, INC. | $48.16 | 2023-2024 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $41.61 | 2023-2024 | |
| Abbvie INC. | $32.54 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.59 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.00 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $25.43 | 2025 | Fanapt |
| Corium, LLC | $25.36 | 2022-2025 | Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $22.80 | 2023 | Ingrezza |
| Amgen INC. | $16.22 | 2023 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.85 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $14.76 | 2023 | Spravato |
| Astrazeneca Pharmaceuticals LP | $14.01 | 2025 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Bourque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.